No recent analyst price targets found for ENDO.
Latest News for ENDO
Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
Strong growth from Vyepti and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ENDO.
U.S. House Trading
No House trades found for ENDO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.